These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 785691)

  • 1. Defibrinogenation treatment in patients suffering from severe intermittent claudication - a controlled study.
    Martin M; Hirdes E; Auel H
    Thromb Res; 1976 Jul; 9(1):47-57. PubMed ID: 785691
    [No Abstract]   [Full Text] [Related]  

  • 2. Therapeutic defibrinogenation in peripheral vascular disease.
    Ernst E
    Int Angiol; 1985; 4(3):373-7. PubMed ID: 3913715
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Hemodilution combined with defibrinogenation.
    Böhme H; Everts B
    Bibl Haematol; 1981; (47):165-72. PubMed ID: 7039611
    [No Abstract]   [Full Text] [Related]  

  • 4. [Studies on blood coagulation systems during defibrinogenation therapy with batroxobin (Bothrops atrox venom) (author's transl)].
    Ishimaru S; Konishi M; Furukawa K; Takahashi M; Fujimaki M
    Rinsho Ketsueki; 1979 May; 20(5):500-9. PubMed ID: 465131
    [No Abstract]   [Full Text] [Related]  

  • 5. The effects of defibrinogenation with batroxobin on endotoxin-induced disseminated intravascular coagulation in rats.
    Yoshikawa T; Murakami M; Furukawa Y; Takemura S; Kato H; Kondo M
    Thromb Res; 1983 Sep; 31(5):729-35. PubMed ID: 6359574
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Therapeutic defibrinogenation as conservative therapy of peripheral arterial occlusive disease. A critical analysis].
    Ernst E
    MMW Munch Med Wochenschr; 1983 Sep; 125(37):796-8. PubMed ID: 6415441
    [No Abstract]   [Full Text] [Related]  

  • 7. Vein surgery during defibrinogenation.
    Browse NL; Clemenson G
    Br J Surg; 1978 Jul; 65(7):452-5. PubMed ID: 149578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Role of natural killer cells in the antimetastatic effect of defibrinogenation with batroxobin].
    Shibuya M; Kawachi S; Aoyama A; Murata A; Baba M; Hirata K; Ohtsuka M; Matsusaka M; Yano T; Niitani H
    Gan To Kagaku Ryoho; 1987 Jul; 14(7):2286-92. PubMed ID: 3300562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Proceedings: Anticoagulation during six hours of extracorporeal perfusion. Comparison between heparinization and defibrinogenation.
    Berglin E; Hansson HA; Teger-Nilsson AC; Williams-Olsson G
    Thromb Diath Haemorrh; 1975 Nov; 34(2):578. PubMed ID: 1198477
    [No Abstract]   [Full Text] [Related]  

  • 10. Defibrinating agents: effects on blood rheology, blood flow and vascular diseases in controlled studies.
    Lowe GD
    Bibl Haematol; 1981; (47):247-51. PubMed ID: 7039612
    [No Abstract]   [Full Text] [Related]  

  • 11. [Therapeutic lowering of fibrinogen levels].
    Ernst E
    MMW Munch Med Wochenschr; 1983 May; 125(21):83-4. PubMed ID: 6410202
    [No Abstract]   [Full Text] [Related]  

  • 12. Experience of extensive vascular surgery on defibrase-defibrinogenated patients.
    Olsson P; Blombäck M; Egberg N; Ekeström S
    Thromb Res; 1976 Sep; 9(3):277-87. PubMed ID: 982350
    [No Abstract]   [Full Text] [Related]  

  • 13. Double-blind trials with ethamsylate, batroxobin or tranexamic acid on blood loss after adenotonsillectomy.
    Verstraete M; Tyberghein J; De Greef Y; Daems L; Van Hoof A
    Acta Clin Belg; 1977; 32(2):136-41. PubMed ID: 331827
    [No Abstract]   [Full Text] [Related]  

  • 14. Effect of defibrination with batroxobin on growth and metastasis of JW sarcoma in mice.
    Chmielewska J; Poggi A; Janik P; Latallo ZS; Donati MB
    Eur J Cancer (1965); 1980 Jul; 16(7):919-23. PubMed ID: 7000518
    [No Abstract]   [Full Text] [Related]  

  • 15. [Reduction of hyperfibrinemia in the nephrotic syndrome using defibrase].
    Salvadori JM; Follana R; Olmer M
    J Urol Nephrol (Paris); 1975 Sep; 81(9):691-6. PubMed ID: 1214313
    [No Abstract]   [Full Text] [Related]  

  • 16. Placebo-controlled, double-blind, two-centre trial of ketanserin in intermittent claudication.
    Bounameaux H; Holditch T; Hellemans H; Berent A; Verhaeghe R
    Lancet; 1985 Dec; 2(8467):1268-71. PubMed ID: 2866336
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Derivatives of fibrinogen and fibrin during defibrase therapy. Separation of high and low molecular weight derivatives of fibrinogen and fibrin by agarose gel filtration.
    Asbeck F; Lechler E; Martin M; van de Loo J
    Haemostasis; 1974; 3(5-6):340-7. PubMed ID: 4468232
    [No Abstract]   [Full Text] [Related]  

  • 18. Placebo-controlled double-blind trial of ketanserin in treatment of intermittent claudication.
    De Cree J; Leempoels J; Geukens H; Verhaegen H
    Lancet; 1984 Oct; 2(8406):775-9. PubMed ID: 6148522
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Relief of chronic arterial obstruction using intravenous brinase. A control study.
    FitzGerald DE; Frisch EP; Milliken JC
    Scand J Thorac Cardiovasc Surg; 1979; 13(3):327-32. PubMed ID: 396673
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Blood viscosity of patients with intermittent claudication--concept of "rheological claudication".
    Dormandy J; Hoare E; Postlethwaite J
    Biorheology; 1976 Jun; 13(3):161-4. PubMed ID: 953251
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.